Finch Therapeutics Group (NASDAQ:FNCH) Trading Down 3.7%

Finch Therapeutics Group, Inc. (NASDAQ:FNCH)’s share price traded down 3.7% on Tuesday . The stock traded as low as $12.07 and last traded at $12.07. 227 shares were traded during mid-day trading, a decline of 99% from the average session volume of 33,381 shares. The stock had previously closed at $12.54.

Finch Therapeutics Group Trading Down 0.8 %

The stock has a market cap of $18.73 million, a price-to-earnings ratio of -1.15 and a beta of 1.25. The stock’s 50-day simple moving average is $6.75 and its 200-day simple moving average is $3.70.

Finch Therapeutics Group (NASDAQ:FNCH) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($3.01) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Finch Therapeutics Group stock. Lake Street Advisors Group LLC acquired a new position in shares of Finch Therapeutics Group, Inc. (NASDAQ:FNCH) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 21,206 shares of the company’s stock, valued at approximately $56,000. Lake Street Advisors Group LLC owned about 1.32% of Finch Therapeutics Group at the end of the most recent reporting period. 21.77% of the stock is owned by institutional investors.

Finch Therapeutics Group Company Profile

Finch Therapeutics Group, Inc, a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates.